Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acorn Asks For More Help From Investors After FDA Panel Denies CorCap PMA

This article was originally published in The Gray Sheet

Executive Summary

Acorn Cardiovascular says it will ask its current investors to fund a confirmatory trial of its CorCap Cardiac Support Device after an FDA advisory panel decided more research is needed before it could support premarket approval

You may also be interested in...



BioVentrix: Reshaping Heart Failure

BioVentrix Inc. is developing a unique, minimally invasive approach to reshaping the heart’s scarred and enlarged left ventricle aimed at patients who develop ischemic heart failure following a heart attack. The company has made considerable headway with its technology, which offers an interesting balance between a catheter-based and surgical-based procedure; however, CEO Kenneth Miller, well aware of the pitfalls that have plagued earlier companies in this field, is taking a cautious approach to the US market.

CorCap gets another shot

FDA will reconsider approval of Acorn Cardiovascular's CorCap mesh wrap treatment for heart failure following completion of a 50-patient confirmatory trial, the firm announces May 9. In December, FDA's Medical Device Dispute Resolution Panel supported the agency's decision not to approve the cardiac support device, based on the firm's 2004 submission of a 300-patient randomized trial (1"The Gray Sheet" Jan. 1, 2007, p. 14). Acorn says it plans to begin the new study, which will have six-month follow-up, this summer, potentially leading to CorCap approval in late 2008 or early 2009. Completion of the trial will require Acorn to "immediately" raise $15 million, the firm says...

CorCap gets another shot

FDA will reconsider approval of Acorn Cardiovascular's CorCap mesh wrap treatment for heart failure following completion of a 50-patient confirmatory trial, the firm announces May 9. In December, FDA's Medical Device Dispute Resolution Panel supported the agency's decision not to approve the cardiac support device, based on the firm's 2004 submission of a 300-patient randomized trial (1"The Gray Sheet" Jan. 1, 2007, p. 14). Acorn says it plans to begin the new study, which will have six-month follow-up, this summer, potentially leading to CorCap approval in late 2008 or early 2009. Completion of the trial will require Acorn to "immediately" raise $15 million, the firm says...

Related Content

UsernamePublicRestriction

Register

MT024318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel